Dr Suzanne Turner
Lymphoma is a heterogeneous disease class consisting of greater than 30 different sub-types and the incidence of this disease has been increasing year on year. In our research we are making progress towards understanding how and why lymphoma develops and hence in the development of new treatments. We investigate a paradigm of lymphomageneis in which a chromosomal translocation leads to the generation of an oncogene and subsequent presumed transformation of T-cells. The oncogene we work with is Nucleophosmin-Anaplastic Lymphoma Kinase (NPM-ALK), a hyperactive tyrosine kinase generated as a result of a translocation between chromosomes 2 and 5. This event is associated with greater than 90% of cases diagnosed as anaplastic large cell lymphoma (ALCL), a mature T-cell malignancy mainly occurring in paediatric patients.
Our research aims to unravel the events leading from the t(2;5) to lymphoma. We use a variety of experimental approaches to reach this goal.
We collaborate with Dr Amos Burke, a paediatric oncologist at Addenbrooke's hospital in Cambridge and are founding members of the European Research Initiative on ALCL (www.ERIALCL.net).